In addition, T cells that invade abemaciclib-treated breast cancer have lower amounts of exhaustion biomarkers such as PD1 and cytotoxic T lymphocyte-associated protein 4 (CTLA4). This evidence concerns the gene CTLA4 and breast cancer.